RecruitingNot ApplicableNCT05241405
Evaluation of the Impact of Taking American Ginseng for 8 Weeks on Fatigue in Patients Treated for Localized Breast or Gynecological Cancer
Evaluation of the Impact of Taking American Ginseng for 8 Weeks on Fatigue in Patients Treated for Localized Breast or Gynecological Cancer - Randomized, Placebo-controlled, Double-blind Study
Sponsor
Centre Francois Baclesse
Enrollment
354 participants
Start Date
Sep 27, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
This is a multicenter randomized trial in breast cancer patients reporting cancer-related fatigue to evaluate the efficacy and safety of Qiseng® based on extract of American ginseng combined with vitamin C from extract of Camu Camu berries
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria7
- Patients with localized breast or gynecological cancer treated as curative adjuvant and/or neoadjuvant chemotherapy and/or adjuvant radiotherapy. These treatments must have been completed within 6 months of inclusion.
- Patient reporting a chronic, stable fatigue state at investigator assessment, defined as a fatigue score ≥ 4 on the visual analog scale rated up to 10, experienced for at least one month
- Maintenance therapy with hormone therapy or other maintenance therapy (trastuzumab, bevacizumab…) is allowed before and/or during the study (except for pembrolizumab, abemaciclib and PARP inhibitors, which are not authorized)
- Patient 18 years of age or older
- Effective contraception in women of childbearing age
- Patient affiliated to a social security plan
- Signed informed consent
Exclusion Criteria14
- Other identified causes of fatigue (anemia of grade \> 2, underlying chronic disease known to be associated with fatigue)
- Ongoing chemotherapy (patients scheduled for oral capecitabine or trastuzumab-emtasin in the adjuvant setting are not eligible)
- Metastatic breast or gynecological cancer
- Ongoing treatment with a tyrosine kinase inhibitor or other P-gp transported molecule or Pembrolizumab or PARP inhibitors
- Patient requiring oral diabetes therapy
- Regular intake of Vitamin C (in addition to what is provided by the diet)
- Patients with chronic pain requiring daily treatment with analgesics, anti-inflammatory drugs or corticosteroids
- Consumption of ginseng-based products in the month prior to inclusion
- Hypersensitivity to any of the components of Qiseng or placebo
- Pregnant or breastfeeding patient
- Simultaneous participation in another therapeutic clinical trial (trial using an experimental product)
- Patient deprived of liberty, under guardianship or curatorship
- Patient unable to undergo the medical follow-up of the trial for geographical, social or psychopathological reasons
- History of any other malignant disease during the last 3 years, except for skin cancer other than melanoma, carcinoma in situ of the uterus. Any other solid tumor or lymphoma (without bone marrow involvement) must have been treated and show no signs of recurrence for at least 3 years
Interventions
DIETARY_SUPPLEMENTQISENG
2 capsules/day for 8 weeks.
DIETARY_SUPPLEMENTPLACEBO
2 capsules/day for 8 weeks.
Locations(10)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05241405
Related Trials
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
NCT069260753 locations
Cardiac Outcomes With Near-Complete Estrogen Deprivation
NCT053096553 locations
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT041190243 locations
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
NCT074780161 location